Since both JMJD6 and EZH2 associate independently with poor prognosis in cancer, the results were extrapolated to clinical samples, and their expression and association was studied in tumor and normal samples; and in publicly available RNA-Seq databases [1, 23–27]. Here, EZH2 is linked to cancer.